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Daniel Voytas: A question for Dana. We now have at our fingertips all these DNA-break-
ing reagents, and you talked about ways to direct the outcomes of repair—homologous 
recombination, non-homologous end-joining—so, in the future do you think that we 
will be able to control the DNA-repair machinery, both in terms of achieving higher 
efficiencies and very predictably the outcomes of the repair.
Dana Carroll: Yes… I’m working on it. Quite a number of people are working on trying 
to improve the efficiency of homologous recombination, which, for a lot of us, is lagging. 
There is a lot of different approaches, and I don’t know if it will come through adding com-
ponents that will enhance homologous recombination, or whether it will come through 
knocking down and joining; maybe there’s an approach that we haven’t anticipated.
Robert Millman (MPM Capital): Dr. Voytas, in your expression system, did you use a 
selectable marker?
Voytas: In my potato example, no selectable marker was used. We knew the framework 
of the technology and expected efficiencies, so we treated the cells and began screening 
to regenerate plants.
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Karen Kindle (Boyce Thompson Institute): Do the invertase mutations have any devel-
opmental, phenotypic or flavor effects? 
Voytas: That’s the next question. We have just generated the products and we hope, with 
the USDA’s approval, to go to the field to fully evaluate the trait.
Patrick Di Bello (University of Arkansas): Has the FDA given you any indication of how 
they will regulate the potatoes?
Voytas: No. The EPA must also consider environmental impact.
Vibha Srivastava (University of Arkansas): Regarding the efficiency of gene targeting, you 
observe 5 percent in potato and 7 percent in tobacco, which are easily transformed, but 
what do you expect in species that are more difficult to transform?
Voytas: For many species, getting the nuclease and the donor molecule into the cell remains 
a challenge. The potatoes were easy because almost every cell was transformed—in excess 
of 80 percent of our cells took up the reagents, so many of the plants that we regener-
ated had the target modifications. This will continue to be a challenge. You might expect 
10 percent of the cells that take up the reagents will undergo the modification you are 
interested in. You have to identify the cells that took up the reagent, and, among those 
identify those that have undergone the gene replacement.
Yinong Yan (Pennsylvania State University): I agree with Dr. Hackett that we should focus 
on the product, not the process. Even though Agrobacterium is a plant pest, regulation 
of Agrobacterium as a vector should be abolished.
Voytas: Opinions rendered so far say that if the product does not have the pathogenic 
sequences, it should not be regulated.
Adam Bogdanove (Cornell University): What do you think is more important: educating 
consumers about the technology or putting forth products that have a clear consumer 
benefit?
Hackett: Regarding educating the general public, I don’t think you can do it. It’s hard 
enough—when I teach undergraduates in genomics—to get them to pay attention to what 
I am talking about, even with the threat of tests. What I am finding—because I make 
maximum use of clickers in the classroom and interrogating the students constantly on 
where they’re at—is that over the past 5 years, and it has just been five years, two obvious 
changes have been occurring, each of which is a sea-change equivalent to the acceptance 
of gay marriage in America. Number one, of incoming freshmen, only 2 percent believe 
that they don’t eat GMO food; ninety-eight percent think either they are, or they might 
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be, eating GMO foods, and it doesn’t concern them in the slightest. Secondly, most 
of them feel that regulatory policies fail to take advantage of recent developments, but 
they also feel that regulatory agencies can be trusted to save them. These numbers and 
trends result from questions to the students before they receive any instruction, in the 
first hour of class.
Voytas: To educate the public presupposes that they understand the subtleties of this 
highly sophisticated technology. As an analogy, when I have dinner with my mother and 
say, “Hey Mom, I’ve whipped up a potato that is resistant to chlorsulfuron.” she is likely 
to respond, “That’s fine, but God already made a perfectly nice potato that I prefer to 
eat.” But, if I say, “Today I whipped up a potato that has less neurotoxin when fried,” 
she might be more predisposed to it. She doesn’t have to understand the subtleties of the 
science and technology, but she can grasp when something is more healthy. This is the 
level of approach appropriate for most of the population.
Hackett: In Brazil, you are allowed to eat transgenic this, that, and the other, and labels 
on the foods have a small yellow triangle that shows a capital “T.” The transgenic products 
sit on the shelf side-by-side with non-transgenic counterparts, and the only difference 
between them is cost. It’s akin to decisions on whether to eat organic or natural produce, 
for which my students don’t really have a feeling for the difference. I trust the Brazilian 
government that the items on the shelf with the “T” are safe, for the most part—like we 
trust “non-organic” to be safe, although we may buy organic.
William Haun (Cellectis Plant Sciences): Perry, one of your slides indicated that one 
founding reason why the system is broken is that the process is regulated, not the product. 
In Canada, they regulate the plant product rather than the process; regulation is triggered 
if the trait is novel. Does that system apply to animals also, and, if so, is it at least a step 
in the right direction?
Hackett: At the Second International Workshop for Regulation of Animal Biotechnology in 
Brazil in August, 2014, a Canadian regulator said that the US policies on transgenic crops 
are “an utter disaster,” and I suggested that, in fact, they are an outstanding example of 
success. So, we couldn’t have been further apart in our views. He didn’t like the clumsiness 
of the statutes, whereas I was looking at the outcome that for 20 years more products in 
more countries with more acreages are being devoted to transgenic crops, especially so 
now that the greatest percentage increases are occurring in developing countries where 
small-scale farmers have the most to gain. In the United States, it is encouraging to see that 
gene-editing of plants is being suggested as not requiring regulatory oversight. However, 
that concept remains under consideration vis-à-vis transgenic animals. The US agency 
that regulates animals has not released a single transgenic animal in a quarter-century; 
they spend so much time trying to expand their control without thinking about revising 
statutes to bring them more into line with twentieth-century technology.
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Greg Martin (Boyce Thompson Institute): Availability of these new methods raises the 
question of how many interesting target genes in plants and animal do we know enough 
about to be in a position to start editing them?
Hackett: This technology is equivalent to high-end computing. When IBM first came 
out with its large computers, the chairman stated that there was need for five of them. 
Now, everyone of us has a laptop, each of which greatly surpasses those “large” comput-
ers in capability. I think that the possibilities of design changes in animals and plants are 
beyond the imagination of anyone in this room.
Voytas: I second that. Thinking back to my PhD work—I spent five years sequencing 30 
kB, whereas it can be done in a millisecond with current technology. And sequencing the 
human genome was beyond imagination. We are talking about one or two genes being 
modified, whereas—in line with Perry’s comments—in a few years we may be able to 
make many dozens of nucleotide changes simultaneously.
Karen Kindle (Boyce Thompson Institute): How do intellectual property issues affect you 
as academics who may wish to see your products in the public domain? Any suggestions 
for researchers, particularly those in small companies?
Voytas: Those in the genome-engineering community have been very good about making 
reagents accessible to help address basic biological questions. If a product arises from a 
targeted modification, that’s when intellectual property has to be taken into consideration. 
A handful of companies have pieces of applicable IP that may have to be accessed for 
commercialization. Good news, in terms of getting the technology more broadly accepted, 
is that we have multiple competing platforms, which, basically, drives down the price. If 
it is too expensive to use a TALEN to modify a tomato, then a CRISPR approach may 
be a valid alternative.
Abel Ponce de León: Where genomic introgression has been achieved, the intellectual 
property is basically on the animal or plant per se, not necessarily on the knowledge. Have 
any of your companies addressed this already, and where are they in the process?
Hackett: We have filed patents on several of the animals, but I would like to go to the 
bigger aspect. It’s unbelievably expensive to get taxpayer investments in basic research back 
to the taxpayers. I started two companies, and it cost me probably a total of $180,000. 
I’m way in the hole right now, but, hopefully, something may come out. To get any of 
this stuff out, whether it’s Sleeping Beauty transposons with chimeric antigen receptors to 
treat cancer or to get some of these animals out to developing-country farmers who need 
them, takes an incredible about of money. Investors are not going to give anybody any 
money to get this technology out to the people who paid for its development in the first 
place, unless there is IP to protect the rest of the development into a product. Actually the 
University of Minnesota holds up the dispersion of the reagents that we have. They have 
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something called a materials transfer agreement, which I hate. I used to share what I had 
until they put a stop to it because they want everything to run through their hands.
Brent Woodward (Cooperative Resources International): Are you willing to tell us more 
about the regulatory minefield faced by Recombinetics?
Hackett: First of all, we are completely open. A request was put out by INAD1 on whether 
or not Recombinetics and other companies were planning on using gene editing with the 
idea that the FDA would be able to have a certain amount of discretion to not demand 
field trials and the like, that would be way too expensive for a small company to afford. 
Such a letter was sent, and retracted a few days later after a meeting with regulators in the 
context of another meeting at which it was realized that this meant that Recombinetics 
was recognizing the legality of the FDA’s position, that gene editing was, actually, under 
their purview. It is our opinion that, in fact, because this is no different from any natural 
mutation—it doesn’t leave any footprint, so to speak, it’s not transgenic DNA in the 
slightest any more—that it really doesn’t have anything to do with better regulations. 
And so, the lawyers actually advised us to retract the letter.
Steve Pueppke (Michigan State University): Is any other country regulating more effec-
tively and doing a better job?
Hackett: Zuoyen Zhu, who was the first scientist to genetically engineer a fish for food, 
in Wuhan, China—growth-enhanced carp—spent a Sabbatical in my lab and gave a 
talk in 1987, in which he said that the fish would be released to the Chinese public in 
1995, approximately, when adequate stocks would be available. A scientist in our group, 
Anne Kapuscinski, asked when trials would be completed to determine safety; he replied, 
1995. In fact, none of these fish have been released, although China needs fish. But they 
have deferred to the United States, as have other regulators in other countries. That’s the 
problem—people are waiting for the United States to do it the right way, thinking that 
we have the most expertise.
Audience Member: Reference has been made to engineering with TALENs and CRISPERs. 
Will they become part of bioengineering modules that will be used in synthetic biology 
or do you see them as distinct approaches?
Voytas: If you think of synthetic biology in terms of constructing new organisms to produce 
products of value, then certainly these TALENs and CRISPERs are enabling tools.
Alan Collmer (Cornell University): Like many other land-grant universities, Cornell has 
sincerely expressed aims such as “knowledge for the public purpose.” I am wondering if 
1Investigational New Animal Drug for the FDA’s Center for Veterinary Medicine (CVM).
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the land-grant university system could be a particularly useful voice for guiding us towards 
more rational regulations and also IP policies that are designed to benefit the public.
Voytas: If you take as a precedent the opinions that have been rendered by the USDA 
on these technologies, I can see going to horticulture departments and saying, “Do you 
want to change the color of your petunias?” or “Do you want to knock out a few genes to 
get rid of anti-nutritionals,” then “Here is the technology, here’s how to do it, go ahead.” 
If the regulatory barrier is broken down, there is no cost to deploying the technology at 
land-grant institutions for practical purposes. Clarity is still tentative; only a few opinion 
letters have been published, but if they reflect the eventual trend, with clearer guidelines 
the technology will be ready to be deployed.
Ponce de León: Let me add something to that. The majority of the members in the North 
American Agricultural Biotechnology Council are land-grant universities, and through 
the Council we are trying to bring to the fore conversations involving various stakeholders 
with interest in making progress with these technologies, including discussing of pros and 
cons. We have to acknowledge as scientists that the regulations have political components 
and regulators have to accommodate both scientific and politic considerations. Through 
our discussions, we hope that by the end of the conference we will develop novel ideas to 
propose alternative solutions to manage the conflict and allow us to move forward.
Ralph Hardy (North American Agricultural Biotechnology Council): And returning to the 
regulatory area, the mistake that was made in the United States in terms of regulations, back 
in the 1980s, was to elect to use existing legislation, This was probably good in the short 
term, but it was disastrous in the long term. We’ve heard about the Canadian situation, 
where they regulate the product rather than the process, and Helen Shearer will address 
this later2. NABC’s 2013 conference focused on the fruit and vegetable area where there 
are very few genetically modified crops. One problem is small market share, which deters 
interest on the part of large companies and the other problem is regulatory. Recently, 
NABC issued a brief white paper suggesting ways of facilitating the commercialization 
of genetically engineered fruits and vegetables3. Also, the National Research Council has 
begun a new study on oversight and regulation of genically engineered crops. My experi-
ence is that our NABC reports are helpful, but those from the NRC carry more weight 
on the Washington scene than most other sources of information. We have a unique 
opportunity to provide that NRC committee with our guidance on how to improve the 
regulatory system, which we should keep in mind during the Tie-Up Session discussion 
at the end of the conference.
2Pages 193–199.
3http://nabc.cals.cornell.edu/Publications/WhitePapers/SpecialtyCrops.pdf.
